Muminov Shavkat
Tashkent Pediatric Medical Institute, Uzbekistan
Scientific Tracks Abstracts: J Nephrol Ther
Aim: study the effect of a combination of valsartan and sacubitril on the functional state of the kidneys in patients with coronary artery disease who underwent revascularization. Materials: All patients were divided into 2 groups according to the prescription of drugs that inhibit the progression of CHF: patients who received the drug valsartan (group B, 160 people), patients who received a combination of the molecule of valsartan sacubitrile(ARNI) in a molar ratio of 1:1 (group C,160 people). Also, all patients were divided into 2 subgroups depending on the degree of eGFR decrease by the 3rd month of observation: patients with a decrease in eGFR by the 3rd month of observation group 1-59 patients and group 2-261. Research results: The study showed that during 2 years of follow-up in patients with coronary artery disease after coronary revascularization. Depending on the performed one, there was no significant difference in the level of eGFR both at baseline and at all stages of observation. The relative dynamics of eGFR was comparable in both groups (by the end of the 3rd month:-17.39±1.17% in group B and-17.03±1.13% in group C; by the end of the first year:-43,62±1.28% and- 40.99± 1.14%;by the end of the second year:-46.50±1.79% and -44.80±1.64%, respectively, differences in the relative dynamics between the groups-nd). \ Conclusion: The present study has demonstrated that the inclusion of ARNI (a combination of valsartan and sacubitrile) in the IHD treatment regimen contributes to a significant decrease in the rate of progression of CKD in patients prone to rapid progression of type II cardiorenal syndrome.
SH.K.Muminov has completed his PhD at the age of 29 years from Tashkent Pediatric Medical Institute. He has published more than 22 papers in reputed journals.
Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report